共 50 条
Immunotherapy and Liver Transplantation The Future or the Failure?
被引:4
|作者:
Tabrizian, Parissa
[1
]
Yu, Allen
[1
]
Debnath, Neha
[1
]
Myers, Bryan
[1
]
Marron, Thomas
[1
]
机构:
[1] Icahn Sch Med Mt Sinai, Recanati Miller Transplantat Inst, Liver Transplant & Hepatobiliary Surg, One Gustave L Levy, New York, NY 10029 USA
关键词:
Liver transplantation;
Hepatocellular carcinoma;
Immunotherapy;
Rejection;
Outcomes;
RESECTABLE HEPATOCELLULAR-CARCINOMA;
ATEZOLIZUMAB PLUS BEVACIZUMAB;
NEOADJUVANT THERAPY;
OPEN-LABEL;
PHASE-III;
TRIAL;
RISK;
PEMBROLIZUMAB;
NIVOLUMAB;
ADJUVANT;
D O I:
10.1016/j.suc.2023.07.009
中图分类号:
R61 [外科手术学];
学科分类号:
摘要:
center dot The increasing demand for liver transplantation (LT) for hepatocellular carcinoma (HCC) has led to the continued efforts to expand LT indications.center dot Immunotherapy has revolutionized the treatment of advanced HCC over the past few years.center dot HCC and other solid tumors exploit evolutionary conserved inhibitory immune checkpoints to evade antitumor immune response by upregulating cognate ligands or receptors capable of inhibiting antitumor immunity.
引用
收藏
页码:163 / 182
页数:20
相关论文